This is from December, 2013, but I found Dr. Loring's comment about the business side of stem cells to be insightful as to why there has not been more work done with this:

"...Autologous cell therapy isn't good from a business point of view, because it lacks economies of scale. However, citing Takahashi's work, Loring said it is the best approach for achieving lasting results with minimal problems to patients."

We can't have that, now, can we---lasting benefit to patient with few problems that will need additional "treatment", all on top of no daily need for drugs! No wonder it is crickets out there for those who are making billions off of the sick.

I guess those comments shed some light on why the larger PD orgs. haven't, to my knowledge, been behind these scientists. The same type of trial is also going to happen in Japan, so we will have two countries using this technology/procedure to judge its safety and efficacy.

Here's the link to the whole article:

http://www.utsandiego.com/news/2013/...hi-stem-cells/